<DOC>
	<DOCNO>NCT01699178</DOCNO>
	<brief_summary>The purpose one year extension ( follow-up ) study gather additional safety data hypogonadal men treat oral TU AndroGel complete 12-month Phase III study CLAR-09007 .</brief_summary>
	<brief_title>Open-label , Follow-up Study Oral Testosterone Undecanoate Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Successful completion CLAR09007</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>